Business Wire

Temenos SaaS Supports Flowe in Launching an Ethical Challenger Bank in Record Time

7.10.2020 10:30:00 EEST | Business Wire | Press release

Share

Temenos (SIX: TEMN), the banking software company, today announced that Banca Mediolanum Group’s digital bank, Flowe, has gone live with Temenos Transact and Financial Crime Mitigation (FCM) delivered as SaaS. Temenos Transact core banking technology enabled Flowe to launch in just five months as Italy’s newest challenger bank aiming to disrupt the market with sustainable and ethical financial services. Flowe launched in record time on Temenos SaaS after a remote implementation during the coronavirus pandemic.

Flowe launched in June 2020 to meet the needs of younger retail banking customers who desire ethical and innovative digital banking. The digital bank provides user-friendly mobile banking experiences and aims to be more eco-friendly than traditional banks. With Temenos SaaS technology, Flowe has the agility required to bring new products to market faster and offer the personalized experiences that customers need. Temenos SaaS combined with the unique ability of the underlying technologies of Temenos Transact will enable Flowe to launch new products at a fraction of the time and differentiate the customer experience.

Flowe provides an account with an Italian IBAN without monthly fees, with the Fun account; ATM withdrawals in the Eurozone are free and the maximum account balance is €10,000. The Flowe card is made from wood that comes from certified forests and it supports reforestation in Guatemala, reduces and offsets CO2 emissions and supports local families. The bank encourages social wellbeing and builds community by enabling users to share expenses. The challenger offers 100% facial recognition onboarding and it is naturally paperless in its operations. Temenos’ API-first technology allows Flowe to cut down deployment time and costs as well as easily connect to third parties. This means that the bank can continuously innovate and update its product lines to meet the changing needs of its audience of young banking consumers.

Temenos SaaS technology enabled the bank to rapidly launch, it offers elastic scalability to support Flowe’s client growth and it dramatically reduces IT costs. Flowe has created a hyper-efficient business model based on Temenos SaaS technology, which enables Flowe to pass on the benefits to its customers.

Temenos’ AI-driven FCM offers the most complete protection against financial crime to improve resiliency and customer experience despite rising cybercrime rates due to coronavirus. Flowe will implement Temenos Payments later this year to provide instant payments in response to heightened demand. Temenos Payments will be integrated with Temenos Transact to provide seamless user experiences and market-leading cost-income ratios.

Temenos worked closely with Flowe to support a remote implementation during the coronavirus pandemic. Temenos’ SaaS technology on Microsoft Azure accelerated the project timelines so that Flowe could launch in five months and address the surge in demand for digital banking. Temenos’ Italy Model Bank provided highly localized, pre-configured banking functionality so Flowe could deploy the technology as is, without customization.

Ivan Mazzoleni, Chief Executive Officer, Flowe, commented: “We are excited to announce this strategic partnership with Temenos. Its cutting-edge technology powered our launch and now fuels our purpose to bring a new standard of sustainable banking to the European market. Temenos’ focus and unparalleled investment in innovation means Flowe will continue to benefit from the most advanced banking technology. Temenos’ SaaS technology helped us to rapidly onboard a significant number of users in a matter of days. It will continue to support our growth as we expand our customer-base and reach new markets but mainly, it will help us in our scope that is empowering people to live a meaningful, sustainable and happy life. Temenos’ open and API-first architecture will help us to continuously innovate and bring to market greener banking products and services as we build our reputation as Italy’s most sustainable digital bank.”

Max Chuard, Chief Executive Officer, Temenos, added: “Congratulations to Flowe for making this inspirational vision for a sustainable financial lifestyle a reality – we are proud to support them. Our partnership with Flowe shows the power of cloud technology and the benefits of SaaS. Temenos Transact and Temenos Financial Crime Mitigation products were remotely delivered as SaaS allowing Flowe to reap the benefits of scalability, efficiency and an elastic cost structure. Temenos is proud to support global digital banks like Flowe as they challenge the status quo and digitalize banking at pace. Temenos market-leading technology and rich expertise means that new digital banks and larger incumbents can gain the agility to innovate and grow, without the restrictions of legacy technology.”

According the recent research from The Economist Intelligence Unit, building a greenfield digital bank remains a top innovation strategy according to 35% of global bank executives.

– Ends –

About Flowe

Flowe is a newly created Benefit, pending BCorp and Carbon Neutral company of Mediolanum Group, which aims to educate young people on the issues of innovation and economic, social and environmental sustainability. In this era of infinite possibilities, where younger generations often feel uncertain about their future and unable to choose a direction, Flowe wants to give young people all the methods and tools to develop their potential and live better. Through its mobile app and the growing ecosystem of partners, Flowe aims to build a BetterBeing Economy to help young people live a more meaningful, sustainable and happy life.

About Temenos

Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.

Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.

For more information, please visit www.temenos.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jessica Wolfe & Scott Rowe
Temenos Global Public Relations
Tel: +1 610 232 2793 & +44 20 7423 3857
Email: press@temenos.com

Annachiara Haerens
Flowe Public Relations
Tel: 39 3494794125
Email: annachiara.haerens@flowe.com

Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye